United BioSource
Founded Year
2003Stage
Unattributed | AliveTotal Raised
$462.82MLast Raised
$23.65M | 5 mos agoAbout United BioSource
United BioSource Corporation is a global pharmaceutical services organization that aims to help to emerge and established life science companies develop and commercialize medical products. UBC specializes in providing new ways to study drugs and devices by offering expertise in science, strategy, and execution. The company was founded in 2003 and is based in Blue Bell, Pennsylvania.
Compete with United BioSource?
Ensure that your company and products are accurately represented on our platform.
United BioSource's Products & Differentiators
Peri- & Post-Approval Studies
UBC’s approach to clinical research and safety puts the focus on real-world data.
Latest United BioSource News
Dec 15, 2022
News provided by Share this article Share this article Effective January 2, 2023, Nathan Thompson will assume the role of Chief Information Officer of UBC BLUE BELL, Pa., Dec. 15, 2022 /PRNewswire/ -- UBC, a biopharmaceutical leader providing integrated clinical, safety, and commercialization services, announced today that Nathan Thompson has joined UBC and, effective January 2, 2023, will assume the role of Chief Information Officer. Nathan joins UBC most recently from Premier Research, where he served as their Chief Information Officer and Head of Corporate Real Estate, and brings more than 20 years of complex technology, operational, and corporate strategy to UBC. With experience spanning the hospital administration and life sciences industries, he will support UBC's vision with a strategic approach to product design through technology innovations. Effective January 2, 2023, Nathan Thompson will assume the role of Chief Information Officer of UBC "As we consider the next level of growth for UBC, we recognize the importance of innovative and differentiated technology solutions as well as technology to drive real world evidence generation" said Patrick Lindsay, President & Chief Executive Officer, UBC. "To ensure UBC's long-term strategic growth, we must have industry-leading products, streamlined IT processes, and effective operational controls in place. I believe that with Nathan's addition to the already outstanding leadership team, we strengthen our evidence-driven model and will continue to be a leader in data-driven decisions and outcomes for the life sciences industry." About UBC United BioSource LLC (UBC) is a leader in the biopharmaceutical market that provides integrated clinical, safety, and commercialization services. UBC combines renowned scientific research and operations experts with innovative technologies, allowing for the best patient and healthcare provider experience. Comprehensive, end-to-end services cover product and patient population characterization during development and market entry, as well as a focus on the patient experience, safety, and adherence. For additional information, visit www.ubc.com. SOURCE United BioSource LLC
United BioSource Frequently Asked Questions (FAQ)
When was United BioSource founded?
United BioSource was founded in 2003.
Where is United BioSource's headquarters?
United BioSource's headquarters is located at 920 Harvest Drive, Blue Bell.
What is United BioSource's latest funding round?
United BioSource's latest funding round is Unattributed.
How much did United BioSource raise?
United BioSource raised a total of $462.82M.
Who are the investors of United BioSource?
Investors of United BioSource include Avista Capital Partners, Medco Health Solutions, J.P. Morgan Chase & Co., Wells Fargo & Company, Capital One and 6 more.
Who are United BioSource's competitors?
Competitors of United BioSource include Avalere Health, Aetion, Sai Life Sciences, Alcala Farma, CXR Biosciences and 13 more.
What products does United BioSource offer?
United BioSource's products include Peri- & Post-Approval Studies and 4 more.
Compare United BioSource to Competitors
Micromyx is a microbiology services company engaged in anti-infective discovery and development for the pharmaceutical, biotechnology, and animal health industries. Founded in 2004 by former pharmaceutical industry infectious disease scientists, Micromyx is a contract research organization that aims to offer clients documented, top-of-the-line laboratory services from experts who have successfully gained FDA approval of new antibiotics.

Sai Life Sciences offers their clients a wide range of integrated drug discovery, development and formulation services, with core expertise founded in synthetic, medicinal and process chemistry and further augmented by a suite of preclinical support services including DMPK, toxicology and formulation that are continually expanding to meet clients' needs.
Veratect offers services that aim to offer the early detection, 24/7 tracking and actionable alert generation of emerging threats (pandemics) worldwide. The company offers the Foreshadow and VeraSight. Per the company, Veratect provides timely and actionable information that supports informed decisions across a broad range of public and private institutions. By identifying emerging risks early, Veratect contends that actions can be taken that save human life, enable loss control, preserve business processes, safeguard supply chain operations and facilities, better manage financial reporting and insurance coverage, and mitigate potential class action lawsuits due to negligence in responding to threats in a timely manner.
Renovo Research is a contract research lab that specializes in crystal form discovery for the pharmaceutical industry.
StemCyte, Inc. is a umbilical cord blood ("UCB") stem cell transplantation and therapeutic products company. StemCyte, headquartered in Southern California has UCB storage facilities in both California and Taiwan which collect, process and store UCB stem cells to be used as therapeutic treatments.
Bridge Laboratories is a preclinical contract research organization (CRO) that aims to provide US-level regulatory compliant drug development services globally. Bridge is US-owned and is headquartered in Gaithersburg, Maryland, with lab facilities in the US and Beijing, China. Bridge is known for its work in toxicology; including a wide variety of in vivo toxicology studies that examine the effect on the immune system, vaccines, developmental and reproductive toxicology, and safety pharmacology. Bridge's AAALAC accredited facility in China was among a labs to perform GLP studies for clients worldwide.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.